Latest Headlines

Latest Headlines

White House spotlights need for electrical implants to treat inflammatory and neurological diseases

President Obama highlighted a $78.9 million BRAIN Initiative project to improve service members' and veterans' health through the development of nano-scale electrical implants to modulate nerve signaling and record health biomarkers.

New antibody-drug conjugate research partnership announced

AB SCIEX and Dalton Pharma Services announced that they are joining forces on R&D of Antibody-Drug Conjugate analysis capabilities.

In India, surgeons use 3-D printed skull for practice

Plastic surgeons in India were able to convert CT scans of a three-year-old girl suffering with craniosynostosis into a physical replica using a 3-D printer. The realistic, life-size model was then used in practice runs of the surgery.

Vascular device drug delivery company surpasses VC goal

Advanced Catheter Therapies' venture capital funding round has been oversubscribed, reflecting investor interest in the company's Occlusion Perfusion Catheter for localized drug delivery in the peripheral vasculature.

Parkinson's play Civitas Therapeutics files for an $86M IPO

The S-1 prominently features Civitas' successful Phase IIb study for an inhaled formulation of levodopa, a "rescue" treatment for Parkinson's patients.

After a string of gene therapy licensing deals, ReGenX says it's time to shine

ReGenX Biosciences is one of the most intriguing gene therapy biotechs you never heard of. And now the executive team in charge intends to start changing that.

Louisiana Tech researchers use 3-D printing to create bioresorbable drug delivery system

Researchers at Louisiana Tech University say they have harnessed 3-D printing for drug delivery by fabricating bioresorbable filaments enabling targeted delivery of antibiotics or chemotherapeutics.

Looking for a Xalkori boost, Pfizer adds targeted med to Merck IO pact

Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.

UPDATED: Kite Pharma spikes on its second take of CAR-T cancer study

Kite Pharma has once again demonstrated just how hot experimental CAR-T technology is in the cancer field. The Santa Monica, CA-based biotech reported Monday evening in a trial update that 12 of 13 evaluable patients with advanced B cell malignancies demonstrated a complete or partial response after being treated with its chimeric antigen receptor (CAR) T cell therapy.

Device to make doctors wash their hands debuts

Biovigil Hygiene Technologies has developed a device that detects when a medical professional enters a patient's room and subsequently issues an alert if the doctor did not wash their hands after patient care.